Kihara James sold $298K of ACAD
Kihara James (PRINCIPAL ACCOUNTING OFFICER) sold 11,421 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $26.08 ($0.30M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale by the principal accounting officer is a new, primary-source datapoint, but the 10b5-1 pre-arranged nature limits interpretive impact.
Market read
Traders may briefly reassess sentiment around ACAD, but the filing alone is unlikely to drive a durable repricing.
What to watch
The article lacks context on total planned volume, whether other insiders bought/sold, and whether the sale was part of a broader compensation/vesting schedule.
Background
The article is an SEC Form 4 insider transaction disclosure for Acadia Pharmaceuticals.
Ticker impact
Acadia Pharmaceuticals insider Kihara James (principal accounting officer) sold 11,421 shares at $26.0846 on a 10b5-1 plan, per Form 4.
Likely minimal near-term price impact; any effect should be short-lived unless paired with other disclosures.
The filing is a Form 4 open-market sale under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales or other insider buys.
Key entities
- issuerACADIA PHARMACEUTICALS INC
US-listed company whose insider transaction is disclosed on Form 4.
- insiderKihara James
Principal accounting officer reporting an open-market sale under a 10b5-1 plan.
